Vibalogics increases capacity with a new 200-L line for virus manufacturing

9 May 2019

Company has also invested in an Äkta-ready chromatography system for downstream processing and liquid handling equipment to deal with increased volumes.

GERMANY-based CDMO Vibalogics has increased its single-use bioreactor and purification capacity with a new manufacturing line to meet increasing demand for its specialist oncolytic virus and viral vector manufacturing services.

Vibalogics increases capacity with a new 200-L line for virus manufacturing

The new manufacturing line features 50-L and 200-L single use bioreactors and a Siemens process control system, further enhancing the company’s state-of-the-art offering within the field of GMP-compliant manufacturing of complex live biologicals.

To complement the new bioreactor, the company has also invested in an Äkta-ready chromatography system for downstream processing and liquid handling equipment to deal with the increased volumes involved in this scale of operation.

Operating from a multi-product BSL-2 facility in northern Germany, Vibalogics specialises in aseptic drug substance and drug product manufacturing of viruses.

Dr Stefan Beyer, managing director at Vibalogics said: “As a leading specialist in the aseptic processing of live biological products, we continue to increase our capacity and scale of operations in line with the growing global demand for these services and already have orders in place for the 200-L system up to the second half of 2020.

“This additional processing capability ensures that we have the necessary infrastructure in place to handle larger batch volumes for our customers.

“We are growing quickly and are now in a position to service a broader customer base for later stage clinical trials and will continue to invest in the technology and equipment needed to meet our customers’ requirements.”

This latest expansion follows the company’s previous addition of an automatic filling line to extend its aseptic fill and finish capability and reinforce its ability to support early-phase biologic supply needs for Phase I and II clinical trials.

Read More

Related news

Improving gut health with human milk oligosaccharides

Improving gut health with human milk oligosaccharides

17 May 2019

2’-FL a very promising agent for digestive health across various age groups beyond infancy.

Read more 
Expert forecasts huge growth in Middle East manufacturing

Expert forecasts huge growth in Middle East manufacturing

16 May 2019

UAE consumers and insurance companies are willing to pay for highest quality drug products.

Read more 
Colorcon's breakthrough for direct compression

Colorcon's breakthrough for direct compression

15 May 2019

New starch-based excipient plays an important role in enhancing the stability of moisture-sensitive APIs.

Read more 
Legacy plans for lyophilisation boom

Legacy plans for lyophilisation boom

14 May 2019

The increase in biologics is driving the growth in demand for lyophilization in vials.

Read more 
Lessons learned from early EU FMD adopters

Lessons learned from early EU FMD adopters

13 May 2019

Data exchange, investment costs, resources and hardware identified as some of the biggest challenges.

Read more 
Catalent achieves global ISO accreditation

Catalent achieves global ISO accreditation

12 May 2019

Company is one of the first CDMOs to receive award.

Read more 
New SIMCA 16 software for multivariate data analytics

New SIMCA 16 software for multivariate data analytics

8 May 2019

Makes model data easier to interpret for better process control.

Read more 
Recipharm launches its end-to-end inhalation offering

Recipharm launches its end-to-end inhalation offering

7 May 2019

Offers a seamless outsourcing service for inhalation products, including MDIs, DPIs and nasal sprays.

Read more 
Accessible online courses designed to improve tablet compression tooling

Accessible online courses designed to improve tablet compression tooling

7 May 2019

I Holland launches online training for all levels of pharmaceutical and nutraceutical professionals.

Read more 
WuXi AppTec acquisition enhances its biometrics services for clinical development

WuXi AppTec acquisition enhances its biometrics services for clinical development

6 May 2019

Acquisition will help customers to shorten time-to-market of new drugs.

Read more